Gout and obesity: new trial tests Weight-Loss drug to lower uric acid
NCT ID NCT07326839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the weight-loss drug orlistat to standard gout treatment helps obese patients lower uric acid levels and reduce gout attacks. 120 adults with gout and obesity will take either orlistat or a placebo for 24 weeks, along with diet and exercise advice. The main goal is to see how many reach a safe uric acid level, with secondary focus on weight loss and inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Northern Theater Command, PLA
Shenyang, Liaoning, 110016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?